Yoshihiko Murata, MD, PhD

Formerly Merck & Co., Inc.
Rahway, New Jersey, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• LB2307 - Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study

  Saturday, October 22, 2022
  2:45 PM – 2:57 PM US ET